Significant out-of-sample classification from methylation profile scoring for amyotrophic lateral sclerosis.
Marta F NabaisTian LinBeben BenyaminKelly Louise WilliamsFleur C GartonAnna A E VinkhuyzenFutao ZhangCostanza L VallergaRestuadi RestuadiAnna FreydenzonRamona A J ZwambornPaul J HopMatthew R RobinsonJacob GrattenPeter M VisscherEilis J HannonJonathan MillMatthew A BrownNigel G LaingKaren A MatherPerminder Singh SachdevShyuan T NgoFrederik J SteynLeanne WallaceAnjali K HendersMerrilee NeedhamJan H VeldinkSusan MathersGarth NicholsonDominic B RoweRobert D HendersonPamela A McCombeRoger PamphlettJian YangIan P BlairAllan F McRaeNaomi R WrayPublished in: NPJ genomic medicine (2020)
We conducted DNA methylation association analyses using Illumina 450K data from whole blood for an Australian amyotrophic lateral sclerosis (ALS) case-control cohort (782 cases and 613 controls). Analyses used mixed linear models as implemented in the OSCA software. We found a significantly higher proportion of neutrophils in cases compared to controls which replicated in an independent cohort from the Netherlands (1159 cases and 637 controls). The OSCA MOMENT linear mixed model has been shown in simulations to best account for confounders. When combined in a methylation profile score, the 25 most-associated probes identified by MOMENT significantly classified case-control status in the Netherlands sample (area under the curve, AUC = 0.65, CI95% = [0.62-0.68], p = 8.3 × 10-22). The maximum AUC achieved was 0.69 (CI95% = [0.66-0.71], p = 4.3 × 10-34) when cell-type proportion was included in the predictor.